Your session is about to expire
← Back to Search
Monoclonal Antibodies
ZW191 for Solid Tumors
Phase 1
Waitlist Available
Research Sponsored by Zymeworks BC Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
* Pathologically or cytologically confirmed diagnosis of cancers with evidence of locally advanced (unresectable), recurrent and/or metastatic disease.
* Measurable disease per RECIST v1.1.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 2 years
Awards & highlights
Summary
The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers.
Eligible Conditions
- Solid Tumors
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to approximately 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Confirmed objective response rate (Part 2)
Incidence of adverse events (AEs; Parts 1 and 2)
Incidence of clinical laboratory abnormalities (Parts 1 and 2)
+1 moreSecondary study objectives
Best overall response (BOR; Part 2)
Clinical benefit rate (Parts 1 and 2)
Confirmed objective response rate (Part 1)
+5 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: ZW191Experimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Zymeworks BC Inc.Lead Sponsor
5 Previous Clinical Trials
1,171 Total Patients Enrolled
Josemund Menezes, MBBS, BCMASStudy DirectorZymeworks BC Inc.
Share this study with friends
Copy Link
Messenger